Lexpos News

Following representations from Community Pharmacy England, the Department of Health and Social Care (DHSC) has re-determined that the following products will be granted special container status from 1 May 2025. Generic drug name (dm+d descriptor) Brand and/or Manufacturer Pack size Special container Budesonide 1mg/2ml nebuliser suspension unit dose ampoules Zentiva Pharma UK Ltd 20 unit [...]

The post 6 products re-classified as a special containers from May 2025 appeared first on Community Pharmacy England.

The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 May 2025. PART IIIA – Professional fees (pharmacy contractors) Contractors should note the English Pharmacy Contractor Single Activity Fee has changed from £1.27 to £1.46. This was [...]

The post Drug Tariff Watch – May 2025 appeared first on Community Pharmacy England.

Following the recent rollout of Electronic Prescription Service (EPS) in detained estates (HM Prisons), NHS England has identified an issue where the patient’s nominated pharmacy details are being populated in the ‘Pharmacy Stamp Area’ of paper FP10 prescriptions and EPS tokens generated by prescribers (including tokens for non-nominated EPS prescriptions). This section would usually be [...]

The post Detained Estate prescribing systems impacting prescription stamp area appeared first on Community Pharmacy England.

Further information and details about margin delivery have been released to help explain the arrangements in a clearer way. Funding arrangements for community pharmacies, particularly the processes around delivery of retained margin, are not straightforward and it can be difficult for pharmacy owners to predict the impact of any changes on their businesses. Since the [...]

The post Contract changes: Margin Explainer appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Brilique 90mg tablets (G Pharma Ltd) Drug alert number: EL(25)A/18 Date issued: 24 April 2025 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Brilique 90mg tablets (G Pharma Ltd) as G Pharma Ltd have informed the MHRA that there is [...]

The post MHRA Class 4 Medicines Defect Notification: Brilique 90mg tablets (G Pharma Ltd) appeared first on Community Pharmacy England.